Studies in the 1970s and 1980s reported that bacterial lysates (BL) had a prophylactic effect on @entity1729 ( @entity1729 ). However, controlled clinical study procedures have evolved substantially since then. We performed a trial using updated methods to evaluate the efficacy of Lantigen B(  ), a chemical BL. This double blind, placebo controlled, multi-center clinical trial had the primary objective of assessing the capacity of Lantigen B to significantly reduce the total number of @entity166 in @entity1 with @entity1729 . Secondary aims were the @entity1729 duration, the frequency and the severity of the acute episodes, the use of drugs and the number of missed workdays. In the subgroup of @entity56 @entity1 with @entity1729 , the number of @entity56 ( @entity56 ) and the use of anti- @entity56 drugs were also evaluated. One hundred and sixty @entity1 , 79 allocated to the @entity15296 ( @entity15296 ) and 81 to the placebo group (PG), were enrolled; 30 were lost during the study and 120 (79 females and 38 males) were evaluated. The PG had 1.43 episodes in the 8-months of follow-up while the @entity15296 had 0.86 episodes (p=0.036). A similar result was observed in the @entity56 @entity1 (1.80 and 0.86 episodes for the PG and the @entity15296 , respectively, p=0.047). The use of antibiotics was reduced (mean 1.24 and 2.83 days of treatment for the @entity15296 and the PG). Logistic regression analysis indicated that the estimated risk of needing antibiotics and NSAIDs was reduced by 52.1 and 30.6%, respectively. With regard to the number of @entity56 , no significant difference was observed between the two groups, but bronchodilators, antihistamines and local corticosteroids were reduced by 25.7%, 56.2% and 41.6%, respectively, in the @entity15296 . Lantigen B significantly reduced the number of @entity166 in @entity1 with @entity1729 . This finding suggests a first line use of this drug for the prophylaxis of @entity166 in these @entity1 .

The bacterial lysate Lantigen B reduces the number of acute episodes in XXXX with recurrent infections of the respiratory tract: The results of a double blind, placebo controlled, multicenter clinical trial.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity15296 :: ('MESH:D019553', 'Disease') :: ['TG', 'treated group'] @entity56 :: ('MESH:D004342', 'Disease') :: ['allergic episodes', 'AE', 'allergic'] @entity1729 :: ('MESH:D012141', 'Disease') :: ['recurrent respiratory tract infections', 'RRTI'] @entity166 :: ('MESH:D003141', 'Disease') :: ['infectious episodes']
@entity1 :: (9606,Species) :: ['patients']
